| | More

COPD Assessment Test (CAT)

Name of questionnaire COPD Assessment Test (CAT)
Type of questionnaire-description Patient-completed questionnaire assessing globally the impact of COPD (cough, sputum, dysnea, chest tighteness) on health status
Number of items 8 (one question assessing impact on sleep)
Number of domains & categories Unidimensional 
Name of categories/domains   N/A
Scaling of items 1 to 5
Scoring  Range of CAT scores from 0–40. Higher scores denote a more severe impact of COPD on a patient’s life. The difference between stable and exacerbation patients was five units. No target score represents the best achievable outcome.
Test-retest reproducibility Reported, intra-class correlation coefficient=0.8 (P.W. Jones, G. Harding, P. Berry, I. Wiklund, W-H. Chen and N. Kline Leidy. Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34: 648–654).
Internal consistency Reported Cronbach’s α=0.88 (P.W. Jones, G. Harding, P. Berry, I. Wiklund, W-H. Chen and N. Kline Leidy. Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34: 648–654)
Validity High correlation with SGRQ (r=0.84) across 7 European countries (Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et al. Properties of the COPD assessment test in a cross-sectional European study. European Respiratory Journal. 2011 July 1, 2011;38(1):29-35.) and r=0.8 in US. (P.W. Jones, G. Harding, P. Berry, I. Wiklund, W-H. Chen and N. Kline Leidy. Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34: 648–654)
Minimally important difference Not determined. Mapping against SGRQ suggests MCID at a group level is 1.6. Experts also suggest that scores <10 have a low impact, 10-20 medium, 21-30 high and >30 very high impact, requiring gradually more interventions (Click Here). 
Language English for UK and the USA
Translations in other languages (if yes, then list the languages) Available in 57 other languages; for an up-to-date list, Click Here
Developer name Paul W. Jones, G. Harding, P. Berry, I. Wiklund, W-H. Chen and N. Kline Leidy
Developer contact information Paul W. Jones
Division of Cardiac and Vascular Science
St George’s University of London
Cranmer Terrace, London, SW17 0RE, UK
E-mail: pjones@sgul.ac.uk
Availability of questionnaire: needs permission from developer, cost or freely available GlaxoSmithKline is the copyright owner of the (CAT). Can find contact information for your country if you Click Here.
References (original publication) P.W. Jones, G. Harding, P. Berry, I. Wiklund, W-H. Chen and N. Kline Leidy. Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34: 648–654.  
Limitations Clinically important minimal difference remains to be rigorously studied
Link to the questionnaire (if available) Click Here
Other comments -
Alternate versions  none